Abstract
The cost-effectiveness andbudget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungary were examined. DPYD testing with ToxNav© was cost-effective in all three countries. In the UK and The Netherlands, the ToxNavstrategy led to more quality-adjusted life yearsand fewer costs to the health systems compared with no genetic testing and standard dosing of capecitabine/5-fluorouracil. In Hungary, the ToxNavstrategy produced more quality-adjusted life years at a higher costcompared with no testing and standard dose. The ToxNavstrategy was found to offer budget savings in the UK and in The Netherlands, while in Hungary it resulted in additional budget costs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
